EIN Presswire: Brain Cancer Press Releases

Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy

Thu, 24 May 2012 13:30:00 +0000

Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy

PR Newswire

- By June 1, a total of 15 clinical centers in the U.S. will be certified to use the NovoTTF™-100A System to treat patients with recurrent glioblastoma multiforme (GBM).

PORTSMOUTH, New Hampshire, May 24, 2012 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced that by June 1, eight additional clinical centers of excellence will join the seven existing clinical centers that provide Novocure's Tumor Treating Fields (TTFields) therapy to patients with recurrent GBM. These fifteen clinical centers are among the leading cancer centers in the U.S.

GBM is both the deadliest and most common form of primary brain tumor in the U.S., diagnosed in approximately 10,000 Americans each year. Based on the literature, the median overall survival time from initial diagnosis for patients with GBM is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the deadliest forms of cancer.

The NovoTTF-100A™ device was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of recurrent GBM. It is available in the U.S. for prescription use from centers whose clinical staff has been trained in the use of the system.

The additional clinical centers and their contacts are:

The Cleveland Clinic, Cleveland, Ohio; Dr. Gene H. Barnett
Arthur G. James Cancer Center, The Ohio State University, Columbus, Ohio; Dr. Robert Cavaliere
The Brain and Spine Tumor Center at USC, Department of Neurosurgery, Los Angeles, CA; Dr. Thomas Chen
Fox Chase Cancer Center, Philadelphia, PA; Dr. Tara Morrison
University of California, San Francisco (UCSF); Dr. Nicholas Butowski
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Dr. Maciej M. Mrugala
Northwestern University, Chicago, IL; Dr. Jeffrey Raizer
Geisinger Health System, Danville, PA; Dr. Steven Toms

These eight new clinical centers join the seven existing centers where NovoTTF therapy has been available for recurrent GBM patients since the end of last year:

Beth Israel Deaconess Medical Center, Boston, Massachusetts; Dr. Eric T. Wong
Mischer Neuroscience Institute in the Memorial Hermann Hospital and The University of Texas Health Science Center, Houston, Texas; Dr. Jay-Jiguang Zhu
New Jersey Neuroscience Institute at JFK, Edison, New Jersey; Dr. Joseph Landolfi
University of Illinois Hospital, Chicago, Illinois; Dr. Herbert Engelhard
NewYork-Presbyterian/Columbia University Medical Center, New York, New York; Dr. Andrew Lassman.
Memorial Sloan Kettering Cancer Center, New York, New York; Dr. Lisa DeAngelis
University of California San Diego Moores Cancer Center, San Diego, California - Dr. Santosh Kesari

"As we continue to expand the number of clinical centers where NovoTTF therapy is provided, including some of the most prestigious cancer centers in the world, our hope is that more patients can be helped with this effective treatment option which does not have the debilitating side effects seen with traditional chemotherapy," said Gabe Leung, Chairman of Global Commercialization. "As more physicians gain clinical experience with NovoTTF therapy, we believe it will take its place as a standard of care for this difficult to treat disease."

TTFields therapy, a novel platform technology for the treatment of solid tumors, provides physicians with a fourth treatment modality for recurrent GBM in addition to surgery, radiation therapy and chemotherapy.

TTFields therapy has been shown in vitro and in vivo to effectively inhibit tumor growth by inducing cell death. TTFields take advantage of the electrical characteristics, geometrical shape and replication rate of dividing cancer cells – all of which makes them susceptible to the effects of alternating electric fields. The therapy is delivered via non-invasive, insulated transducer arrays that are placed directly on the skin in the region of the tumor. TTFields therapy is frequency-tuned to target cancer cells and avoid harming normal cells. It creates an artificial, alternating electric field within the tumor which disrupts cancer cell division and can cause complete destruction of the dividing cancer cells.

About the NovoTTF-100A System

The NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy. The most commonly reported side effect from NovoTTF-100A treatment was a mild-to-moderate rash beneath the transducer arrays. The NovoTTF-100A has received marketing approval in the U.S. and is a CE Marked device that is cleared for sale in Europe.

The US Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically– or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.novottftherapy.com or by calling toll free +1-855-281-9301.

About Novocure

Novocure Limited is a private oncology company pioneering a novel therapy for solid tumors. Novocure's worldwide headquarters is located in the Jersey Isle. Novocure's U.S. operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com

Media contacts:

Peter Melnyk
Pmelnyk@novocure.com
+1-631-697-7457

Frank Leonard
Fleonard@novocure.com
+1-215-854-4095

Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy

Thu, 24 May 2012 13:30:00 +0000

Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy

By June 1, a total of 15 clinical centers in the U.S. will be certified to use the NovoTTF™-100A System to treat patients with recurrent glioblastoma multiforme (GBM).

PR Newswire

PORTSMOUTH, N.H., May 24, 2012 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced that by June 1, eight additional clinical centers of excellence will join the seven existing clinical centers that provide Novocure's Tumor Treating Fields (TTFields) therapy to patients with recurrent GBM. These fifteen clinical centers are among the leading cancer centers in the U.S.

The additional clinical centers and their contacts are:

The Cleveland Clinic, Cleveland, Ohio; Dr. Gene H. Barnett
Arthur G. James Cancer Center, The Ohio State University, Columbus, Ohio; Dr. Robert Cavaliere
The Brain and Spine Tumor Center at USC, Department of Neurosurgery, Los Angeles, CA; Dr. Thomas Chen
Fox Chase Cancer Center, Philadelphia, PA; Dr. Tara Morrison
University of California, San Francisco (UCSF); Dr. Nicholas Butowski
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Dr. Maciej M. Mrugala
Northwestern University, Chicago, IL; Dr. Jeffrey Raizer
Geisinger Health System, Danville, PA; Dr. Steven Toms

These eight new clinical centers join the seven existing centers where NovoTTF therapy has been available for recurrent GBM patients since the end of last year:

Beth Israel Deaconess Medical Center, Boston, Massachusetts; Dr. Eric T. Wong
Mischer Neuroscience Institute in the Memorial Hermann Hospital and The University of Texas Health Science Center, Houston, Texas; Dr. Jay-Jiguang Zhu
New Jersey Neuroscience Institute at JFK, Edison, New Jersey; Dr. Joseph Landolfi
University of Illinois Hospital, Chicago, Illinois; Dr. Herbert Engelhard
NewYork-Presbyterian/Columbia University Medical Center, New York, New York; Dr. Andrew Lassman.
Memorial Sloan Kettering Cancer Center, New York, New York; Dr. Lisa DeAngelis
University of California San Diego Moores Cancer Center, San Diego, California - Dr. Santosh Kesari

About the NovoTTF-100A System

About Novocure

Media contacts:

Peter Melnyk
Pmelnyk@novocure.com
(631) 697-7457

Frank Leonard
Fleonard@novocure.com
(215) 854-4095

SOURCE Novocure

More Retired NFL Players Added to Lawsuit Against NFL

Thu, 24 May 2012 07:12:06 +0000

14 additional players are joining the roster of retired football players suing the NFL for purposefully attempting to hide a well-known link between concussions and permanent brain injury.

BEAUMONT, TX, May 24, 2012 /24-7PressRelease/ -- 14 additional players are joining the roster of retired football players suing the NFL for purposefully attempting to hide a well-known link between concussions and permanent brain injury.

The group filing suit now totals 46, says attorney Matthew C. Matheny of the Provost Umphrey law firm.

"These players are suffering permanent brain injury that they and their families must endure for the rest of their lives as a result of playing for the National Football League. Its time for the NFL to admit they have known for years about the connection between multiple concussions and brain damage as a result of being allowed or forced to return to play before if was medically safe for the player to do so ."

Among the players suing the NFL are Minnesota Vikings hall of fame player John Randle, who retired in 2003, and hall of fame running back Eric Dickerson. The complaint alleges the NFL failed to research, inform and take reasonable action to mitigate the risks associated with multiple concussions, thereby breaching its duty to the players.

The NFL oversees America's most popular spectator sport, football, and acts as a trade association for 32 franchise owners. The NFL governs and promotes the game of football, sets and enforces rules. The teams share a percentage of the League's overall revenue. NFL revenues far exceed any other sports league, frequently surpassing $7 billion annually.

For more than forty years, board certified personal injury lawyer Walter Umphrey's law firm, Provost Umphrey's mission has remained to seek justice for those suffering from a personal injury, wrongful death or other legal wrong across Texas and nationwide through their lawyers in Beaumont and Houston, Little Rock, Arkansas and Nashville, Tennessee.

For more information please contact

Miranda Sevcik, (713) 515-9729

www.provostumphrey.com

---

Press release service and press release distribution provided by http://www.24-7pressrelease.com

Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer

Wed, 23 May 2012 14:30:00 +0000

Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer

Data shows strong correlation between validated prostate cancer gene biomarkers in prostate cancer tissue and urinary exosomes

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today presented two clinical studies demonstrating the potential utility of non-invasive sampling of patients' urine to detect and manage prostate cancer.

In the first study, the presence of a prostate cancer-specific biomarker in exosomes collected from random patients' urine samples demonstrated a strong correlation to the presence of that marker in prostate tissue removed via radical prostatectomy (RP). The study also correlated the expression level of the marker in urine with the likelihood of a positive cancer biopsy.

In a second study, urinary exosomes demonstrated elevated levels of survivin messenger RNA (mRNA) from patients with castration-resistant prostate cancer (CRPC) following primary therapy. Survivin expression has been implicated in hormone-independent prostate cancer growth.

"These studies, led by our director of research, Dr. Leileata Russo and conducted by our clinical collaborators, are part of our prostate cancer in vitro molecular diagnostics program," said James McCullough, chief executive officer of Exosome Diagnostics. "The urinary exosome provides us with a stable source of RNA that we can interrogate using qPCR to non-invasively analyze different stages of prostate cancer."

Motamedinia et al. (abst. # 2108) obtained random samples of urine from men and measured the concordance of prostate cancer with detection of the biomarker, TMPRSS2:ERG (T:E). The investigators found that TMPRSS2:ERG expression occurred in 17 of 21 post-RP tissue samples. They also found that T:E expression in urinary exosomes from non-digital rectal exam (DRE) patients was nine-fold higher in the prostate biopsy positive patients versus biopsy negative patients. The study also demonstrated a high level of concordance between exosome-biomarker signature and the marker's presence in cancerous prostate tissue.

"The diagnosis and management of prostate cancer and patients with elevated PSA remains challenging for both patients and their physicians," said James McKiernan, M.D., the John and Irene Given professor of Urology, director of Urologic Oncology, Columbia University Medical Center and co-author of the study. "Patients with high PSA results must decide whether to undergo a biopsy procedure, which in itself may not be definitive as further suggested from the results of the study. A reliable, non-invasive diagnostic test that can determine the presence and nature of a prostate malignancy as well as its response to treatment would be of great value. The biofluid-based technology highlighted in this study is a very promising approach to reaching this goal."

Lin et al. (abst. # 2232), investigated the relationship of survivin expression measured in exosomes and the disease status of patients diagnosed with CRPC. The presence of survivin, an inhibitor of apoptosis, has been implicated as a factor in hormone-independent tumor growth. Survivin expression was higher in patients with measurable disease than in patients without disease and this was correlated with castration resistance.

"Monitoring patient response to treatment is largely limited to PSA testing and new tools are needed," said Daniel Petrylak, M.D., associate professor of medicine, Columbia University Medical Center and co-author of the study. "The non-invasive biofluid test we employed in this study directly measures one component of the genetic profile of malignant prostate cells. This approach should enable us to better understand a patient's response to treatment and, if an alternative therapy is required, an analysis of exosome RNA and DNA content could better direct a treatment decisions."

Exosomes are one of many different sub-populations of microvesicles that can be isolated from biofluids such as blood, urine and cerebrospinal fluid (CSF). Exosomes are shed by cells under both normal and pathological conditions. These vesicles contain high quality RNA and DNA that can be extracted and purified for analysis.

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into all biofluids, including blood, urine and CSF, forming a stable source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural stability to achieve high sensitivity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. Exosome Diagnostics' development program is focused on blood, urine and cerebrospinal fluid with programs in collaboration with the Prostate Cancer Foundation in prostate cancer and Accelerate Brain Cancer Cures in brain cancer. The Company maintains facilities in New York, St. Paul, MN and Munich, Germany. For more information, please visit www.exosomedx.com.

SOURCE Exosome Diagnostics

Research Finds Hope For Brain Injury Sufferers

Tue, 22 May 2012 07:10:11 +0000

Traumatic brain injury (TBI) affects more than 1.7 million people every year, including many in Illinois. TBI is caused by a sudden impact to the brain, causing injury to the skull and is often the result of automobile accidents and falls.

CHICAGO, IL, May 22, 2012 /24-7PressRelease/ -- Traumatic brain injury (TBI) affects more than 1.7 million people every year, including many in Illinois. TBI is damage to the brain caused by sudden blow, movement, impact or penetrating injury to the skull, often the result of automobile accidents and falls. Concussions are actually traumatic brain injuries.

Brain tissue can be bruised or more seriously damaged from even minor traumas. Blood vessels in the brain may be ruptured, with blood loss and pressure inside the skull, impairing the circulation of blood to the brain and robbing the brain of oxygen. TBI symptoms can include unconsciousness, headache, fatigue, nausea, dizziness, moodiness, cognitive and attention deficit and memory problems. Agitation, weakness and difficulty with physical coordination are other common symptoms. Fifty-thousand TBI victims die annually, and another 85,000 a year have lingering disabilities requiring long-term care. Recently concussions associated with traumatic brain injuries have been discovered in professional football players, and what had previously been considered to be relatively minor problems has proven instead to be life changing, and even life-threatening in some cases.

About 5 million people now live with the after-effects of TBI. The annual cost of caring for people injured and disabled by TBI is an estimated $56 billion, including indirect expenses arising from inability to work and contribute to society as well as direct costs of therapy and medications. Many victims of TBI obtain legal representation to help them recover funds to pay for their injuries.

Besides treating those afflicted with TBI, both immediately and for the long term, medical attention focuses on preventing traumatic brain injuries in the first place and on research that might limit the damage of a TBI.

Prevention And Treatment Of Brain Injuries

The most obvious preventive measures are common-sense ones: routine use of seat belts for occupants of motor vehicles and helmets for skiers, snowboarders, hockey and football players, and those riding bicycles, motorcycles and horses. Parents can instill habits in their children that will help protect them from traumatic brain injury throughout life. Fall prevention, through measures like providing handrails on steps and stairs, is also important.

Once an injury occurs, immediate treatment aims to keep a damaged brain from getting worse before it gets better. Inflammation at the site of the injury can spread and affect more brain cells; as more brain cells die, the injured person's chance of sustaining serious permanent effects increases.

Researchers have found that chemicals the body naturally produces can be useful in minimizing TBI damage. One scientist recently reported that estrone, a natural form of estrogen, can help TBI victims.

In that medical study, rats were injured and soon afterward were given either a placebo or estrone. Those who received estrone benefited markedly because the estrone supported production of a factor in the brain that promotes cell survival. The research also showed how inflammation travels along cell pathways, an important step in being able to intercept the spread of damage and preserve more brain cells immediately after a TBI.

Financially Surviving A Traumatic Brain Injury

The recent research findings support hope that the human and financial costs of TBI can be reduced, so that fewer individuals and their families will be so heavily impacted by these devastating injuries. One very important tool for many brain injury victims and their families is a personal injury lawsuit brought against the parties who caused these traumatic brain injuries.

Brain injury treatment is incredibly costly and victims often require around-the-clock medical care. Families of TBI victims sometimes face bankruptcy after accumulating medical expenses, but a civil suit can often recover financial compensation to offset the health-related costs of a TBI injury while also compensating the victim and family for their suffering. To discuss your legal remedies, contact an experienced Chicago brain injury attorney.

The partners at the law firm of Lane & Lane, LLC are highly respected throughout the Illinois legal community. We have more than 130 years of combined legal experience. Our members have held leadership roles in the most prestigious legal organizations at the local, state and national level.

The Law Offices of Lane & Lane, LLC

230 W Monroe Street, Suite 1900

Chicago, Il 60606

Phone: 312-957-4656

Toll Free: 877-585-7311

Website: www.lane-lane.com

---

Press release service and press release distribution provided by http://www.24-7pressrelease.com

Study Results of Novocure's NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer

Mon, 21 May 2012 14:26:57 +0000

Study Results of Novocure's NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer

Data Show that NovoTTF™ Therapy was Comparable to Physicians' First Chemotherapy Choice in Clinical Efficacy with Better Quality of Life Outcomes in Patients with Recurrent Glioblastoma

PR Newswire

PORTSMOUTH, N.H., May 21, 2012 /PRNewswire/ -- Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer (Stupp R. et al., NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomized phase III trial of a novel treatment modality, Eur J Cancer(2012), http://dx.doi.org/10.1016/j.ejca.2012.04.011). The study showed that NovoTTF™ therapy was comparable to active chemotherapy in extending overall survival, with minimal side effects and far better quality of life.

Novocure™, a commercial stage private oncology company, manufactures the device, NovoTTF™-100A, a wearable device that delivers TTFields, or alternating electrical fields, specifically tuned to disrupt the uncontrolled division of cancer cells, resulting in cell death.

This is the first publication in a peer reviewed journal of the Phase 3 trial of chemotherapy-free treatment with NovoTTF monotherapy (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent GBM. The primary endpoint of the trial was overall survival. The secondary endpoints were progression-free survival at six months, 1-year survival rate, and quality of life.

Patients enrolled in the Phase 3 trial had a median age of 54 years (range 23-80) with a Karnofsky performance status of 80% (range 50-100). Patients were randomized to NovoTTF alone (n=120) or active chemotherapy control (n=117). The average number of prior non-TTField treatments was two (range 1-6). At a median follow-up of 39 months, median survival was 6.6 versus 6.0 months (hazard ratio 0.86 [95% CI 0.66-1.12]; p=0.27), one-year survival rate was 20% and 20%, and progression-free survival rate at six months was 21.4% and 15.1% (p=0.13), in NovoTTF and active control patients, respectively. Radiological responses were comparable (14% versus 9.6%, p=0.19), with 3% complete responses seen only in the NovoTTF arm.

The most common NovoTTF-related adverse events were principally mild (14%) to moderate (2%) skin rash beneath the device's transducer arrays. Severe adverse events occurred in 6% of patients treated with NovoTTF vs 16% for those treated with chemotherapy (p=0.02). Quality of life analyses favored NovoTTF therapy in most domains, including vomiting, nausea, pain, diarrhea, constipation, and cognitive and emotional functioning.

"The patients treated within this trial had very, very advanced disease. Most of our patients rapidly become independent in handling the device and loved having a treatment without the need for chemotherapy," said Dr. Roger Stupp of the University of Lausanne, lead author of the study. "We are encouraged by our findings and the future groundbreaking potential of NovoTTF therapy in this tough-to-treat disease and other cancer."

The study's co-principal investigator Dr. Philip Gutin, Chair of the Department of Neurosurgery and Co-Executive Director of the Brain Tumor Center at Memorial Sloan Kettering Cancer Center in New York said, "Patients who have GBM face significant challenges, and we as physicians currently have limited treatment options. This study shows that a new, safe and effective treatment option is now available."

"The results of this important trial clearly show that a fourth treatment modality now exists for patients with recurrent GBM," said Asaf Danziger, Novocure's Chief Executive Officer. "We are working closely with many of the leading cancer centers in the world to make NovoTTF therapy available to their patients, and will continue to develop this new cancer fighting weapon to improve the lives of people suffering from this disease."

About Glioblastoma

Glioblastoma (GBM) is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. Historically, based on literature, the median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the deadliest forms of cancer.

About the NovoTTF™-100A System

NovoTTF™-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in both in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy. The NovoTTF-100A has received marketing approval in the US and is a CE Marked device that is cleared for sale in Europe.

Approved Indication

The US Food and Drug Administration (FDA) approved the NovoTTF-100A System in April 2011 for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically– or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

About Novocure™

Novocure™ Limited is a private oncology company pioneering a novel therapy for solid tumors. Novocure's worldwide headquarters is located in the Jersey Isle. Novocure's US operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Media contacts:

Frank Leonard
Fleonard@novocure.com
(215) 854-4095

Peter Melnyk
Pmelnyk@novocure.com
(212) 767-7534

SOURCE Novocure

Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory

Mon, 21 May 2012 13:47:16 +0000

Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory

PR Newswire

BUFFALO, N.Y., May 21, 2012 /PRNewswire/ -- Kinex Pharmaceuticals, LLC and Xiangxue Pharmaceuticals announced today the execution of a license agreement from Kinex Pharmaceuticals granting Xiangxue Pharmaceuticals exclusive rights to KX02, for all oncology indications, in the greater China territory (China, Hong Kong, Taiwan) and Singapore.

KX02, a lipophilic dual src/pretubulin inhibitor, was discovered and developed by Kinex Pharmaceuticals through their internal R&D efforts. It is a small molecule that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including cells (T98G) that are resistant to Temodar, the most widely used chemotherapy for the treatment of malignant glioma. In a well-established brain tumor animal model, KX02 has been shown to consistently clear brain tumors after 4 weeks of therapy in 30-60% of treated animals. Pharmacokinetic studies showed that KX02 is absorbed orally and has 76% penetration to brain tissue from plasma. Mechanistic studies showed that KX02 induced both surface and central necrosis of the glioma compared to Temodar which only induced surface necrosis. All preclinical studies, including toxicology studies in two animal species, essential for the filing of investigational new drug application (IND) to the US Food and Drug administration (FDA), have been completed. Kinex Pharmaceuticals is planning to file an IND in early third quarter of 2012 to initiate phase 1 clinical studies. The intellectual property of KX02 as a new chemical entity is protected by issued patents until February 2026.

The acquisition of rights to develop drugs in certain Asian territories is part of Xiangxue Pharmaceuticals overall business strategy to expand their small molecule franchise, including their effort to work on new drug development, into those regions that have intellectual property protection. This strategy is in line with the overall direction that is being encouraged by the Chinese government in order for Chinese Pharmaceutical companies to engage in new drug discovery and development.

This collaboration will allow Kinex Pharmaceuticals to access Xiangxue Pharmaceuticals experience in clinical research and will also allow access to a large population of patients with brain tumors, the intended indication for KX02. Developing medicine to help patients is the main objective for both Kinex and Xiangxue Pharmaceuticals.

Under the terms of the agreement, Xiangxue Pharmaceuticals will acquire the rights to the development and commercialization of KX02 for all oncology indications in greater China, including China, Hong Kong, Taiwan, and Singapore. Xiangxue Pharmaceuticals will assume all development responsibility and associated costs in the licensed territory and will collaborate with Kinex Pharmaceuticals during this process. Xiangxue Pharmaceuticals will provide Kinex Pharmaceuticals with an up-front payment, development milestone payments and royalties associated with product sales. Xiangxue will also make a strategic investment in Kinex equity. A joint development team will be established to foster this collaboration.

Mr. YongHui Wang, Chairman and CEO of Xiangxue Pharmaceuticals, states: "This collaboration is an important strategic decision for Xiangxue Pharmaceuticals and will facilitate the ability of our Company to further expand our small molecule pipeline portfolio. We were very impressed by the experience of the management team at Kinex Pharmaceuticals during our due diligence process. Xiangxue Pharmaceuticals will be able to contribute to the development of KX02 in China and we are excited to collaborate with the scientific team of Kinex Pharmaceutical and to explore the potential synergy in the overall development of KX02 for patients with brain tumors. This strategic relationship will create significant value for both companies."

Xiangxue Pharmaceuticals is one of the leading pharmaceutical companies in China and has established a strong Research and Development team that is focused on the field of oncology.

"We are delighted to have the opportunity to collaborate with Xiangxue Pharmaceuticals to develop KX02. We are impressed by the high scientific standards of their research team and advisors, as well as the management team's strong commitment to research and development. Kinex will benefit from the scientific and local experience of Xiangxue Pharmaceuticals in the global development of KX02," states Johnson Yiu-Nam Lau, MD, FRCP, Chairman and CEO of Kinex Pharmaceuticals, who was former Chairman and CEO of Ribapharm, a publicly traded company previously listed in the New York Stock Exchange.

"The collaboration with Xiangxue Pharmaceuticals will allow us to accelerate the clinical development of KX02. I am delighted to have the opportunity to work closely with their clinical development team." stated Chief Medical Officer of Kinex Pharmaceuticals, Dr. Rudolf Kwan, who was previously Vice-President of Clinical Research, at Schering-Plough Research Institute.

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica™ and Opal™ to discover and develop novel drugs for oncology and immuno-modulatory diseases. Through a licensing and collaborative agreement, Kinex is also developing products based on the Orascovery technology platform initially developed by Hanmi Pharmaceuticals. More information on Kinex Pharmaceuticals can be found at www.kinexpharma.com

Kinex Pharmaceuticals, LLC Caution Regarding Forward-looking Information

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

About Xiangxue Pharmaceuticals, Co., Ltd

Guangzhou Xiangxue Pharmaceutical Co., Ltd (XPH) is a publicly traded pharmaceutical company headquartered in Guangzhou, China. The primary business of the Company is the manufacturing and marketing of pharmaceutical products, including herbal medicines, western medicines and biomedical engineering products. The company is actively expanding its product pipeline through research and development efforts and through in-licensing in areas of unmet medical needs. More information on XPH can be found at www.xphcn.com.

Kinex Inquiries:

Lyn M. Dyster, Ph.D.
VP, Operations
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
USA

E-mail: ldyster@kinexpharma.com

SOURCE Kinex Pharmaceuticals

Dr. Ekkehard Kasper Selected For Patients' Choice Award 2011

Fri, 18 May 2012 19:30:00 +0000

Dr. Ekkehard Kasper Selected For Patients' Choice Award 2011

PR Newswire

Dr. Ekkehard Kasper of Boston, MA has been ranked among the top physicians in the nation based on patient reviews.

BOSTON, May 18, 2012 /PRNewswire-USNewswire/ -- A select few physicians were honored with the prestigious 2011 Patients' Choice Award, and this year they include Dr. Ekkehard Kasper.

(Photo: http://photos.prnewswire.com/prnh/20120518/DC10014)

Only doctors who have received top scores by their patients and pass other quality measures are awarded the Patients' Choice Award. In fact, of the nation's 720,000 active physicians, just 5 percent were accorded this honor in 2011.

Every month, millions of patients across the U.S. access websites like Vitals (http://www.vitals.com) to share feedback about their experiences with their doctors. Patients rate various components of the care they receive, such as the accuracy of their diagnosis, the amount of time they spent with the doctor, and the doctor's bedside manner and follow-up care. Patient's Choice ranks the top reviewed physicians and looks at other quality measures to compile its yearly list.

Dr. Ekkehard Kasper commented on the recognition: "This is quite an honor for me. I am very pleased to have been selected and grateful to my patients who went out of their way to rate me and give me positive reviews."

About Dr. Ekkehard Kasper: a short profile by and about the honoree:

Dr. Kasper has been trained in several exceptional institutions. He obtained a doctorate from Oxford University in the UK and a medical doctorate from Freiburg University (Germany) before subspecialty training in neurosurgical oncology and functional neurosurgery by Christoph Ostertag, MD at Freiburg University as well as a full neurosurgical residency at Harvard (Massachusetts General Hospital) under Robert Martuza, MD. He's been directing the brain tumor program at Beth Israel Deaconess Medical Center since 2005 as faculty member of Harvard Medical School.

For more information on this Patients' Choice Award winner, please visit Dr. Ekkehard Kasper's profile on PatientsChoice.org.

Following the publication of Dr. Ekkehard Kasper's selection for the Patients' Choice Award, American Registry seconded the honor and added Dr. Kasper to The Registry™ of Business Excellence. An exclusive recognition plaque has been designed to commemorate the honor. The doctor's custom wall plaque is shown here.

For more information on Dr. Ekkehard Kasper, located in Boston, MA please call 617-632-7246, or visit http://www.bidmc.org/CentersandDepartments/Departments/Surgery/Neurosurgery/OurTeam/Neurosurgeons.aspx.

This press release was written by American Registry, LLC with approval by and/or contributions from Dr. Kasper and was distributed by PR Newswire, a subsidiary of UBM plc.

Patients' Choice provides in depth information on doctors in your area who have been recognized and awarded for outstanding patient care and expertise. The Patients' Choice Award is the honor roll of physicians who have received the highest ratings by their patients.

American Registry, LLC, recognizes excellence in top businesses and professionals. The Registry™ includes over 2 million significant business and professional recognitions. For more information, search The Registry at http://www.americanregistry.com.

Contact Info:
Dr. Ekkehard Kasper
Phone: 617-632-7246

SOURCE American Registry

Northwest Bio Provides Update On DCVax®-L Brain Cancer Trial

Thu, 17 May 2012 12:30:00 +0000

Northwest Bio Provides Update On DCVax®-L Brain Cancer Trial

Amendment Accepted By FDA, Enhancing and Upgrading the Trial

41 US Clinical Trial Sites Now In Operation

PR Newswire

BETHESDA, Md., May 17, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it now has 41 clinical trial sites open and recruiting across the United States in its ongoing clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. This is ahead of the Company's previous projection of 40 sites by the end of Q2, 2012. The Company plans to continue adding clinical trial sites in the US and Europe, and expects to have at least 60 sites open and enrolling by the end of Q3, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The Company also announced that the FDA has accepted an amendment of the clinical trial, which does not make any change in the treatment regimen, which leaves all data collected to date intact for use in the trial's overall results, and which includes the following:

Designation as a Phase III trial
Expanded and enhanced statistical endpoint analyses
Addition of another cohort of patients which can potentially expand the application of DCVax®-L, and which increases the trial to up to 300 patients
Addition of interim analyses for efficacy

A description of the trial protocol as amended will be available at www.clinicaltrials.gov.

Linda Powers, CEO of Northwest Bio, commented, "Of course, the evolution of this trial to a Phase III trial is no assurance of the outcome, and more than one Phase III trial can often be required for a product approval unless the clinical results are particularly strong. However, we are pleased to make this transition to Phase III, and believe that the package of amendments further enhances an already strong trial, positioning the Company to realize the potential of the DCVax® technology."

Ms. Powers added, "We are excited about the operational progress we have made on multiple fronts, through long periods of work building to these points, as described in our recent announcements. Our lead clinical trial has grown and emerged as a 300-patient, international Phase III trial involving some of the best institutions in the US, UK and Germany. We are also working on several other initiatives, and will provide reports when milestones are reached in those programs."

For further information about the Company and its programs, please visit the Company's website at www.nwbio.com.

About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead clinical trial is a Phase III trial, with up to 300 patients with newly diagnosed GBM for whom surgery is indicated. GBM is the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer.

Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax^® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Northwest Biotherapeutics, Inc.	t (240) 497-9024	www.nwbio.com
4800 Montgomery Lane	f (240) 627-4121	OTCBB: NWBO
Suite 800
Bethesda, MD 20814

SOURCE Northwest Biotherapeutics, Inc.

Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012

Wed, 16 May 2012 22:00:00 +0000

Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012

LUX-Lung 3 clinical trial data selected for late-breaking oral presentation

PR Newswire

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012. LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use pemetrexed/cisplatin as a comparator in this population.

The presentation of the LUX-Lung 3 trial will shed light on a distinct and specific NSCLC patient population, those with EGFR mutations. EGFR mutations occur in 10 to 15 percent of NSCLC patients, and are well-established predictive biomarkers that provide specific targets for therapeutic intervention in NSCLC.

Title

Lead Author

Presentation details

LUX-Lung 3: A randomized,
open-label, phase III study of
afatinib versus pemetrexed and
cisplatin as first-line treatment for
patients with advanced
adenocarcinoma of the lung
harboring EGFR-activating mutations.

James Chih-Hsin Yang, MD, PhD

Oral Abstract #LBA7500

Date: Monday, June 4
Time: 3:00 PM-3:15 PM CDT

"We are excited to share the results of our pivotal LUX-Lung 3 trial, the largest and most robust ever conducted in EGFR mutation-positive patients," said Berthold Greifenberg, M.D., Vice President, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "We are continuously advancing the development of our oncology pipeline and look forward to opportunities to contribute to the body of scientific knowledge in this area."

Additional Presentations of Boehringer Ingelheim Investigational Compounds

In addition to the LUX-Lung 3 presentation, more than 15 studies of Boehringer Ingelheim's investigational therapies have been selected for inclusion at ASCO, demonstrating the company's innovative clinical development program across a variety of cancer types.

Select Poster Presentations
Title	Lead Author	Poster details
*Afatinib*
LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy.	Heikki Joensuu, MD, Professor	Abstract #TPS647 Poster #15B Date: Saturday, June 2 Time: 8:00 AM - 12:00 PM CDT

LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.	Nadia Harbeck, MD, PhD	Abstract #TPS649 Poster #15D Date: Saturday, June 2 Time: 8:00 AM - 12:00 PM CDT

LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L).	Tamas Hickish, MD	Abstract # TPS651 Poster #15F Date: Saturday, June 2 Time: 8:00 AM - 12:00 PM CDT

LUX-head and neck 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.	Jean-Pascal H. Machiels, MD, PhD	Abstract # PS5598 Poster #32H Date: Saturday, June 2 Time: 1:15 – 5:15 PM CDT

LUX-head and neck 2: A randomized, double- blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.	Barbara Burtness, MD	Abstract # TPS5599 Poster # 33A Date: Saturday, June 2 Time: 1:15 – 5:15 PM CDT
*Nintedanib*
TRICC-c: BIBF 1120 versus placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)—A multicenter, randomized phase II trial in progress.	Andreas Berger, MD	Abstract # TPS3636 Poster # 39A Date: Monday, June 4 Time: 8:00 AM - 12:00 PM CDT
*Volasertib*
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.	Herlinde Dumez	Abstract # 3018 Poster #10 Date: Saturday, June 2 Time: 1:15 – 5:15 PM CDT

About Lung Cancer

Lung cancer is the second most common cancer and kills more people than any other cancer. In 2012, approximately 226,160 new cases of lung cancer will be diagnosed in the United States, with 160,340 Americans dying from the disease. NSCLC is the most common form, accounting for about 85 percent of all lung cancers.[1] Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options.

About Afatinib

Afatinib is an investigational compound. Afatinib is not approved by the FDA; its safety and efficacy have not been established.

Afatinib is an investigational oral, once-daily irreversible ErbB Family Blocker that specifically inhibits epidermal growth factor receptor (EGFR or ErbB1), human epidermal receptor 2 (HER2 or ErbB2), ErbB3 and ErbB4. It is currently in phase III clinical development in NSCLC, head and neck and breast cancer.

About the Afatinib Clinical Trial Program in Advanced NSCLC

The LUX-Lung studies evaluate the use of afatinib in various settings of advanced NSCLC, including in patients harboring EGFR mutations and those with recurrent disease. These trials include:

LUX-Lung 1, a Phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and the reversible EGFR TKIs erlotinib or gefitinib.
LUX-Lung 2, a Phase II trial evaluating afatinib in NSCLC patients with EGFR mutations (EGFR M+), either treatment-naive or after one line of treatment with chemotherapy.
LUX-Lung 3, a Phase III trial investigating afatinib as a first-line treatment in patients with advanced NSCLC with EGFR mutations.
LUX-Lung 4, a Phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment.
LUX-Lung 5, a global Phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized Phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.
LUX-Lung 6, a Phase III trial investigating the efficacy and safety of afatinib compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations.
LUX-Lung 7, a Phase IIb trial evaluating afatinib head-to-head versus gefitinib as a first-line treatment in EGFR M+ NSCLC patients. Patient recruitment for this trial has recently initiated.
LUX-Lung 8, a Phase III trial evaluating afatinib head-to-head versus erlotinib in second-line treatment of squamous cell carcinoma of the lung. Patient recruitment for this trial has recently initiated.

For more information on these trials, please visit www.clinicaltrials.gov.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.

The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. Afatinib is an investigational orally-administered irreversible inhibitor of the ErbB family of receptor tyrosine kinases, which is currently in phase III clinical development in advanced NSCLC, head and neck cancer, and breast cancer. Nintedanib (BIBF 1120) is an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis and is currently in phase III clinical development in NSCLC and ovarian cancer. Volasertib is an investigational inhibitor of polo-like kinase that is currently being investigated in early phase trials. Boehringer Ingelheim's oncology pipeline continues to evolve and demonstrates the company's continued commitment to the disease area.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

References

[1] American Cancer Society. Cancer Facts and Figures: 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Last accessed April 27, 2012.

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.

In Vitro Diagnostics - A Global Market Overview

Tue, 15 May 2012 12:10:02 +0000

In Vitro Diagnostics - A Global Market Overview

PR Newswire

NEW YORK, May 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

In Vitro Diagnostics - A Global Market Overview

http://www.reportlinker.com/p0862275/In-Vitro-Diagnostics---A-Global-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

`The In Vitro Diagnostic (IVD) industry has been confronting a range of issues, such as regulations, industry consolidation, reforms in healthcare, low level of technological innovations and ever-changing demographics. Though some of these challenges may seem insurmountable, the glimmer of hope always exists that could rejuvenate the IVD industry over the coming years. Improvement in healthcare infrastructure, growth in personalized medicine based on bespoke solutions and companies' focus towards growth-centric emerging markets certainly constitute some of the major factors that can be looked up to.

The arrival of novel technologies and innovations has spawned assays and biomarkers that would play crucial roles in the high-growth areas of infectious diseases, women's health, cancer and cardiovascular conditions. Molecular diagnostics and the genomic reform have been the primary drivers of this growth, which are expected to sustain this level not only by tailoring existing drug therapies for individual patients, but also through developing new drug therapies that would enable in the better identification of patient populations that could prospectively benefit from drug treatment. Companies would do well to concentrate on tests based on biomarkers, such as those utilizing protein-based biomarkers for Alzheimer's disease, and the genomic revolution, with solutions using gene-based testing for indicating the probability of a range of cancers.

Though it may seem that the IVD industry is at a vital crossroad, looking hither and thither, the key point remains focusing on the above-mentioned areas to garner adequate standing that would enable in a complete turnaround. Personalized medicine appears to be a crucial aspect that has to be looked into with detail, so as to ascertain where the future of this industry lies.

The report reviews, analyses and projects IVD market for global and the regional markets including North America, Europe, Asia-Pacific, South America and Rest of World. The regional markets further analyzed for 22 independent countries across North America – United States, Canada and Mexico; Europe – Western Europe (Germany, France, Italy, Spain, United Kingdom, Belgium, Netherlands, Switzerland, Portugal, Austria, Greece, Scandinavia and Rest of Western Europe) and Eastern Europe (Poland, Czech Republic, Russia and Rest of Eastern); Asia-Pacific –Japan, China, India and Rest of Asia-Pacific; South America – Argentina, Brazil and Rest of South America; and Rest of World.

Market for IVD product categories analyzed in this study includes Reagents & Consumables and Instruments & Systems. The report also includes the market analysis for end-use application analysis of IVDs – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology.

This 493 page global market report includes 284 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product category and application area. The report comprises the brief business profiles of 47 key global players and 60 major players across the United States – 36; Europe – 18; and Asia-Pacific – 6. The report also provides the listing of the companies engaged in research and development, equipment manufacturing, processing, supplies and distribution of In Vitro Diagnostics. The global list covers the addresses, contact numbers and the website addresses of 382 companies.

TABLE OF CONTENTS:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION1.1 Product Outline1.1.1 Positives1.1.2 Precision of IVDs1.1.3 Type of Products Used For In Vitro Diagnostics1.1.3.1 General Purpose Reagents1.1.3.2 Analyte Specific Reagents1.1.3.3 Biochemical and Chemical Reagents: An Overview1.1.3.3.1 Opting for the Optimal Biochemical and Chemical Reagents for IVD Tests

2. A SNAPSHOT OF END-USE APPLICATIONS

2.1 Clinical Chemistry

2.1.1 Clinical Chemistry Analyzers

2.2 Immunoassays

2.2.1 Objective of Immunoassays

2.2.2 Immunoassay Methodologies

2.3 Diabetes Testing

2.3.1 Primary Types of Diabetes

2.3.2 Prediabetes

2.3.3 Diagnosis of Diabetes and Prediabetes

2.3.3.1 Fasting Plasma Glucose (FPG) Test

2.3.3.2 Oral Glucose Tolerance Test (OGTT)

2.3.3.3 Random Plasma Glucose Test

2.4 Blood Testing

2.4.1 Categories of Blood Tests

2.4.1.1 Complete Blood Count (CBC)

2.4.1.2 Red Blood Cells

2.4.1.3 White Blood Cells

2.4.1.4 Platelets

2.4.1.5 Hemoglobin

2.4.1.6 Hematocrit

2.4.1.7 Mean Corpuscular Volume (MCV)

2.4.2 Blood Chemistry Tests/Biochemical Analysis

2.5 Molecular Diagnostics

2.5.1 Molecular Diagnostics Techniques

2.5.2 Molecular Diagnostics and Genome Research

2.5.3 Molecular Diagnostics Tools

2.5.3.1 Sample Collection and Preparation

2.5.3.2 Amplification and Detection Platforms and Assays

2.5.3.3 Software Tools

2.5.3.4 Complete Solutions

2.5.4 What the Future Holds for Molecular Tools

2.6 Pathology

2.6.1 Anatomical Pathology

2.6.2 Chemical Pathology

2.6.3 Clinical Pathology

2.6.4 Forensic Pathology

2.6.5 General Pathology

2.6.6 Genetic Pathology

2.6.7 Hematology Pathology

2.6.8 Immunopathology

2.6.9 Microbiology

2.7 Microbiology

3. KEY MARKET TRENDSGlucose Levels to be Measured via Breath with New Diabetes DeviceNew Technology to Protect Insulin in AfricaDepressed? Get a Blood Test3-D Microscopy Assistance for Cell AnalysisBacteria-Based Test Strips for Detecting Glucose Levels in Diabetics in the OffingMid-2012 Set Timeline for FDA for Issuing Final Guidance for In Vitro Companion Diagnostics- The 2011 Draft Guidance- Companion Diagnostic TestsDiabetes Testing Made Easier with New TechnologyIn-Vitro Nanodiagnostics to Detect Pathogens: Contemporary TrendsClinical Laboratories Offer Physicians New Diagnostic Technology for Speedier and Better DiagnosisNew Blood Test to Detect Alzheimer's Five Years BeforehandEarly Diagnosis of Cryptococcosis Aided by New Rapid Blood TestDiagnosis of Mesothelioma Could be Done Earlier with New Blood TestChallenges Confronting Western Europe's In Vitro Diagnostics Industry and Probable Solutions- Introduction- Challenges Faced by the Industry- What the Industry Needs to Accomplish"Cry" for Measuring Blood Glucose LevelsDiabetes Care Alleviated with New Tool that Saves Time and Reduces Error RisksFuture Role of Metabolomic and Genomic Profiling in Diabetic Clinical Medicine- Introduction- Metabolomic Profiling in Clinical MedicineDiagnosing Heart Attacks with a New Blood Test- Problems Associated with Paucity in Diagnostic Tests- PrognosisGenome Wide Association Study in South Asia Reveals New Genes Related to DiabetesField-Based Molecular Diagnostic Test for African Sleeping Sickness on the HorizonEnhancing Type 2 Diabetes Therapies with Mobile Phone TechnologyProstate Cancer Detection to be Improved with New 'Biomarker' Blood TestRegulation of Molecular Diagnostic AssaysBreast Cancer Detection via Blood Test and its PossibilityA Trouble-Free Blood Test for Detecting Lung CancerBlood Glucose Monitoring Advancements- Watch Monitors- Lifesaving Tattoos- Contact LensesNew Blood Test Technology for Detecting Alzheimer's DevelopedMigrating Cancer Cells Perceived with New Blood TestOne Drop of Blood Required for Lab-On-A-Chip DeviceNew DNA Blood Test for Detecting Down's Syndrome in Pregnant WomenNew Molecular Diagnostic Technology for Cervical Cancer Developed by European Researchers- Expression of Genes- mRNA Detective- The Major ChallengeSingle-Cell Molecular 'Fingerprints' for Brain Tumors Generated using New Diagnostic ChipIn Vitro Diagnostics' Initiatives in the Battle to Combat Heart Conditions- IVD and Immunoassays- Point-of-Care Technology- Evolution of Cardiac Markers- POC Immunoassay Platforms: What the Future Holds

4. KEY GLOBAL PLAYERS

3M Company

Abbott Laboratories, Inc.

Affymetrix, Inc.

Agilent Technologies, Inc.

Alere Inc

Arkray, Inc.

B.R.A.H.M.S GmbH

Baxter International Inc.

Bayer AG

Beckman Coulter, Inc.

Becton, Dickinson And Company

BG Medicine, Inc.

Biocartis NV

bioMérieux SA

Bio-Rad Laboratories, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Caliper Life Sciences, Inc.

Celera Corporation

Celgene Corporation

China Medical Technologies, Inc.

Covidien PLC

Danaher Corporation

EMD Millipore

F. Hoffmann-La Roche Ltd.

GE Healthcare Ltd.

Gen-Probe Incorporated

Hitachi Chemical Diagnostics

Johnson & Johnson

Kaneka Corporation

Merck KGaA

Meridian Bioscience, Inc.

MP Biomedicals LLC

Novartis AG

Novo Nordisk A/S

Olympus Corporation

Perkinelmer, Inc.

Pfizer Inc

Qiagen N.V.

Roche Diagnostics Corporation

Roche Holding Ltd.

Sekisui Diagnostics LLC

Shanghai Kehua Bio-Engineering

Siemens AG

Siemens Healthcare Diagnostics Inc.

Sigma-Aldrich Corporation

Thermo Fisher Scientific Inc.

5. KEY BUSINESS TRENDSAbbott and Genetics Laboratory, Inc in an AgreementAbbott and Merck in an AgreementARKRAY, Inc to Introduce SPOTCHEM™ CL SB-1440Samsung Acquires Nexus division of ITC Nexus Holding CompanyAffymetrix's GeneChip® System 3000Dx v.2 for In Vitro Clinical Diagnostic Use Cleared by China's State Food and Drug AdministrationRoche, Life Technologies in Licensing AgreementsAbbott and University of North Texas (UNT) Health Science Center in CollaborationMultifunctional Cholesterol Meter Device from Eternity HealthcareDako and Amgen Enter into an AgreementmiRInform Pancreas Test Introduced by AsuragenVetScan Canine Lyme Rapid Test Launched by AbaxisSiemens Forms Two New Companion Diagnostics CollaborationsLife Technologies and DaAn Gene Establish Chinese Joint VentureRemote Glucose Monitor from MedtronicBionime to Offer GE-Branded Diabetes SolutionsQIAGEN Forms Two Agreements with US Biotech CompaniesAgilent Technologies and Integrated Diagnostics in a PartnershipMicronics Taken Over by SonyEnhanced Immunoassay Specificity and Accuracy from Thermo Fisher ScientificIn Vitro Diagnostic Test for Chagas Disease from AbbottProteome Sciences Unveils In Vitro AssaysSiemens, Illumina in an AllianceImmunoassay Solution for Rapid Detection of Synthetic Cannabinoids from RandoxMultiGEN Diagnostics Acquired by TrovaGeneLife technologies in an Agreement with GlaxoSmithKline3500 Dx Series Genetic Analyzers for In Vitro Diagnostics Introduced by Life Technologies in ChinaGE Commits US$1 Billion for Cancer R&DQuidel Molecular Diagnostics Assays to be Distributed by Life Technologies in EuropeNew Version of MicroRNA Screening Product from HTG Molecular DiagnosticsEMD Millipore Takes Over AmnisQIAGEN and Pfizer Enter into CollaborationIVD Reagents Portfolio from SDIX ExpandedSurModics® Assay Diluent (Protein-Free) Launched by SurModicsSiemens and JEOL in a PartnershipC. difficile GDH Immunoassay Launched by Pro-Lab DiagnosticsbioMérieux Takes Over ARGENEmtm laboratories AG Taken Over by RocheLabchip® Dx from Caliper Bestowed with CE IVD MarkApo B Antibody for the IVD Market Launched by SDIXSeegene in Partnership with SamsungLandmark Salmonella Detection Technology Introduced by bioMérieuxHealthMed Services Acquires DRS TechnologiesMolecular Diagnostic Test for Detecting Food-Borne Pathogens from VeredusRoche and Merck in CollaborationSiemens' IMMULITE 2000 XPi Immunoassay System Cleared by the USFDAMyconostica Ltd Acquired by Lab21Qiagen Acquires CellestisQIAGEN and Merck Collaborate with Government of RwandaTecan and Sword Diagnostics Introduce a New Immunoassay Detection TechnologyGeneChip® miRNA 2.0 Array Launched by AffymetrixNovartis and Grifols in an Agreement to Commercialize Diagnostic ProductsBiocartis, Janssen Pharmaceutica NV in a Molecular Diagnostics PartnershipJ&J and Massachusetts General Hospital in CollaborationbioMérieux, Philips Achieve a LandmarkSeptin9 Blood Testing Service for Colorectal Cancer Launched by Warnex in CanadabioMérieux, Biocartis in a Molecular Diagnostics AllianceQIAGEN, Abbott in an AgreementAbbott's Enhanced FreeStyle Lite® Blood Glucose Test Strips Launched in AustraliaNew Automated Modular Testing Platform for Molecular Diagnostics from QIAGENcobas e 602 Immunoassay Module Launched by RocheIH 1000 Automated Blood Screening System Launched by Bio-RadPhilips' Technology Platform for Automated DNA/RNA Molecular Diagnostic Testing Acquired by Biocartis

6. GLOBAL MARKET OVERVIEW

6.1 Market Overview by Product Type

6.2 Market overview by Application Area

6.3 IVD Product Type Overview by Geographic Region

6.3.1 IVD Reagents & Consumables

6.3.2 IVD Instruments & Systems

6.4 IVD Application Area Overview by Geographic Region

6.4.1 Clinical Chemistry

6.4.2 Immunoassay

6.4.3 Diabetes Testing

6.4.4 Blood Testing

6.4.5 Molecular Diagnostics

6.4.6 Pathology

6.4.7 Cellular Analysis

6.4.8 Microbiology

PART B: REGIONAL MARKET PERSPECTIVEDeveloped Vs. Developing WorldCan Recession be a Factor Worthy of Consideration?Scenario in HospitalsWhat is in Store

REGIONAL MARKET OVERVIEW

1. NORTH AMERICA1.1 Market Overview by Geographic Region1.2 Market Overview by Product Type1.3 Market Overview by Application Area1.4 IVD Product Type Overview by North American Region1.4.1 Reagents & Consumables1.4.2 Instruments & Systems1.5 IVD Application Area Overview by North American Region1.5.1 Clinical Chemistry1.5.2 Immunoassay1.5.3 Diabetes Testing1.5.4 Blood Testing1.5.5 Molecular Diagnostics1.5.6 Pathology1.5.7 Cellular Analysis1.5.8 Microbiology1.6 Major Market Players3M Company (United States)Abbott Diabetes Care, Inc. (United States)Abbott Diagnostics Inc (United States)Abbott Laboratories, Inc. (United States)Abbott Molecular Inc. (United States)Affymetrix, Inc. (United States)Agilent Technologies, Inc. (United States)Alere Inc (United States)Baxter International Inc. (United States)Beckman Coulter, Inc. (United States)Becton, Dickinson And Company (United States)BG Medicine, Inc. (United States)Bio-Rad Laboratories, Inc. (United States)Bristol-Myers Squibb Company (United States)Caliper Life Sciences, Inc. (United States)Celera Corporation (United States)Celgene Corporation (United States)Danaher Corporation (United States)EMD Millipore (United States)Gen-Probe Incorporated (United States)Hitachi Chemical Diagnostics (United States)Hologic Inc (United States)Instrumentation Laboratory (United States)Johnson & Johnson (United States)Life Technologies Corporation (United States)Meridian Bioscience, Inc. (United States)MP Biomedicals LLC (United States)Ortho-Clinical Diagnostics Inc. (United States)Perkinelmer, Inc. (United States)Pfizer Inc (United States)Roche Diagnostics Corporation (United States)Roche Molecular Systems Inc. (United States)Sekisui Diagnostics LLC (United States)Siemens Healthcare Diagnostics Inc. (United States)Sigma-Aldrich Corporation (United States)Thermo Fisher Scientific Inc. (United States)

1.7 North American Market Overview by Country

1.7.1 United States1.7.1.1 Market Overview by Product Type1.7.1.2 Market Overview by Application Area

1.7.2 Canada

1.7.2.1 Market Overview by Product Type

1.7.2.2 Market Overview Application Area

1.7.3 Mexico1.7.3.1 Market Overview by Product Type1.7.3.2 Market Overview Application Area

2. EUROPE

2.1 Market Overview by Geographic Region

2.2 Market Overview by Product Type

2.3 Market Overview by Application Area

2.4 Major Market Players

Axis-Shield Plc (United Kingdom)

B.R.A.H.M.S GmbH (Germany)

Bayer AG (Germany)

Bayer Healthcare AG (Germany)

Biocartis NV (Belgium)

bioMérieux SA (France)

Boehringer Ingelheim GmbH (Germany)

Covidien Plc (Ireland)

F. Hoffmann-La Roche Ltd. (Switzerland)

GE Healthcare Ltd. (United Kingdom)

Merck KGaA (Germany)

Novartis AG (Switzerland)

Novo Nordisk A/S (Denmark)

Qiagen N.V. (The Netherlands)

Roche Holding Ltd. (Switzerland)

Siemens AG (Germany)

Siemens Healthcare (Germany)

Trinity Biotech Plc (Ireland)

2.5 European Market Overview by Region

2.5.1 Western Europe

2.5.1.1 Market Overview by Geographic Region

2.5.1.2 Market Overview by Product Type

2.5.1.3 Market Overview by Application Area

2.5.1.4 IVD Product Type Overview by Western Europe Region

2.5.1.4.1 Reagents & Consumables

2.5.1.4.2 Instruments & Systems

2.5.1.5 IVD Application Area Overview by Western Europe Region

2.5.1.5.1 Clinical Chemistry

2.5.1.5.2 Immunoassay

2.5.1.5.3 Diabetes Testing

2.5.1.5.4 Blood Testing

2.5.1.5.5 Molecular Diagnostics

2.5.1.5.6 Pathology

2.5.1.5.7 Cellular Analysis

2.5.1.5.8 Microbiology

2.5.1.6 Western Europe Market Overview by Country

2.5.1.6.1 Germany

2.5.1.6.1.1 Market Overview by Product Type

2.5.1.6.1.2 Market Overview by Application Area

An Appraisal from the Recent Past

2.5.1.6.2 France2.5.1.6.2.1 Market Overview by Product Type2.5.1.6.2.2 Market Overview by Application AreaRecent Past: An Assessment

2.5.1.6.3 Italy

2.5.1.6.3.1 Market Overview by Product Type

2.5.1.6.3.2 Market Overview by Application Area

A Peek into the Recent Past

2.5.1.6.4 Spain2.5.1.6.4.1 Market Overview by Product Type2.5.1.6.4.2 Market Overview by Application AreaWhat the Recent Past Revealed and its Future Effect

2.5.1.6.5 The United Kingdom

2.5.1.6.5.1 Market Overview by Product Type

2.5.1.6.5.2 Market Overview by Application Area

The United Kingdom's Past, Current and Future IVD Trends

2.5.1.6.6 Belgium2.5.1.6.6.1 Market Overview by Product Type2.5.1.6.6.2 Market Overview by Application Area

2.5.1.6.7 The Netherlands

2.5.1.6.7.1 Market Overview by Product Type

2.5.1.6.7.2 Market Overview by Application Area

2.5.1.6.8 Switzerland2.5.1.6.8.1 Market Overview by Product Type2.5.1.6.8.2 Market Overview by Application AreaReimbursement Proving to be a Major Setback

2.5.1.6.9 Portugal

2.5.1.6.9.1 Market Overview by Product Type

2.5.1.6.9.2 Market Overview by Application Area

Scenario in the Recent Past

2.5.1.6.10 Austria2.5.1.6.10.1 Market Overview by Product Type2.5.1.6.10.2 Market Overview by Application Area2009 Vs. 2010

2.5.1.6.11 Greece

2.5.1.6.11.1 Market Overview by Product Type

2.5.1.6.11.2 Market Overview by Application Area

A Greek Tragedy

2.5.1.6.12 Scandinavia2.5.1.6.12.1 Market Overview by Product Type2.5.1.6.12.2 Market Overview by Application Area

2.5.1.6.13 Rest of Western Europe

2.5.1.6.13.1 Market Overview by Product Type

2.5.1.6.13.2 Market Overview by Application Area

2.5.2 Eastern Europe2.5.2.1 Market Overview by Geographic Region2.5.2.2 Market Overview by Product Type2.5.2.3 Market Overview by Application Area2.5.2.4 IVD Product Type Overview by Eastern Europe Region2.5.2.4.1 Reagents & Consumables2.5.2.4.2 Instruments & Systems2.5.2.5 IVD Application Area Overview by Eastern Europe Region2.5.2.5.1 Clinical Chemistry2.5.2.5.2 Immunoassay2.5.2.5.3 Diabetes Testing2.5.2.5.4 Blood Testing2.5.2.5.5 Molecular Diagnostics2.5.2.5.6 Pathology2.5.2.5.7 Cellular Analysis2.5.2.5.8 Microbiology

2.5.2.6 Eastern Europe Market Overview by Country

2.5.2.6.1 Poland2.5.2.6.1.1 Market Overview by Product Type2.5.2.6.1.2 Market Overview by Application Area

2.5.2.6.2 Czech Republic

2.5.2.6.2.1 Market Overview by Product Type

2.5.2.6.2.2 Market Overview by Application Area

2.5.2.6.3 Russia2.5.2.6.3.1 Market Overview by Product Type2.5.2.6.3.2 Market Overview by Application Area

2.5.2.6.4 Rest of Eastern Europe

2.5.2.6.4.1 Market Overview by Product Type

2.5.2.6.4.2 Market Overview by Application Area

3. ASIA-PACIFIC3.1 Market Overview by Geographic Region3.2 Market Overview by Product Type3.3 Market Overview by Application Area3.4 IVD Product Type Overview by Asia-Pacific Region3.4.1 Reagents & Consumables3.4.2 Instruments & Systems3.5 IVD Application Area Overview by Asia-Pacific Region3.5.1 Clinical Chemistry3.5.2 Immunoassay3.5.3 Diabetes Testing3.5.4 Blood Testing3.5.5 Molecular Diagnostics3.5.6 Pathology3.5.7 Cellular Analysis3.5.8 Microbiology3.6 Major Market PlayersArkray, Inc. (Japan)China Medical Technologies, Inc. (China)Kaneka Corporation (Japan)Olympus Corporation (Japan)Shanghai Kehua Bio-Engineering (China)Sysmex Corporation (Japan)

3.7 Asia-Pacific Market Overview by Country

3.7.1 Japan3.7.1.1 Market Overview by Product Type3.7.1.2 Market Overview by Application Area

3.7.2 China

3.7.2.1 Market Overview by Product Type

3.7.2.2 Market Overview by Application Area

3.7.3 India3.7.3.1 Market Overview by Product Type3.7.3.2 Market Overview by Application Area

3.7.4 Rest of Asia-Pacific

3.7.4.1 Market Overview by Product Type

3.7.4.2 Market Overview by Application Area

4. SOUTH AMERICA4.1 Market Overview by Geographic Region4.2 Market Overview by Product Type4.3 Market Overview by Application Area4.4 IVD Product Type Overview by South American Region4.4.1 Reagents & Consumables4.4.2 Instruments & Systems4.5 IVD Application Area Overview by South American Region4.5.1 Clinical Chemistry4.5.2 Immunoassay4.5.3 Diabetes Testing4.5.4 Blood Testing4.5.5 Molecular Diagnostics4.5.6 Pathology4.5.7 Cellular Analysis4.5.8 Microbiology

4.6 South American Market Overview by Country

4.6.1 Argentina4.6.1.1 Market Overview by Product Type4.6.1.2 Market Overview by Application Area

4.6.2 Brazil

4.6.2.1 Market Overview by Product Type

4.6.2.2 Market Overview by Application Area

4.6.3 Rest of South America4.6.3.1 Market Overview by Product Type4.6.3.2 Market Overview by Application Area

5. REST OF WORLD

5.1 Market Overview by Product Type

5.2 Market Overview by Application Area

PART C: GUIDE TO THE INDUSTRY1. NORTH AMERICA1.1 Canada1.2 United States

2. EUROPE

2.1 Belgium

2.2 Denmark

2.3 Finland

2.4 France

2.5 Germany

2.6 Ireland

2.7 Italy

2.8 Norway

2.9 Spain

2.10 Sweden

2.11 Switzerland

2.12 The Netherlands

2.13 United Kingdom

3. ASIA-PACIFIC3.1 Australia3.2 China3.3 Hong Kong3.4 Japan3.5 Malaysia3.6 New Zealand3.7 Singapore3.8 South Korea3.9 Thailand

4. REST OF WORLD

4.1 Israel

PART D: ANNEXURE1. RESEARCH METHODOLOGY2. THE QUESTIONNAIRE3. FEEDBACKCharts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

Chart 1: Classification of IVD Reagents and Instruments by Application Area

Chart 2: Global IVD Market (2012 & 2018) in Clinical Chemistry Applications by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 3: Global IVD Market (2012 & 2018) in Immunoassay Applications by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 4: Global IVD Market (2012 & 2018) in Diabetes Testing Applications by Geographic Region – North America, 7Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 5: Global IVD Market (2012 & 2018) in Blood Testing Applications by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 6: Global IVD Market (2012 & 2018) in Molecular Diagnostics Applications by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 7: Global IVD Market (2012 & 2018) in Pathology Applications by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 8: Global IVD Market (2012 & 2018) in Microbiology Applications by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 9: Global In Vitro Diagnostics Market Analysis (2008-2018) in USD Million

Chart 10: Global In Vitro Diagnostics Market Analysis (2008-2018) by Product Type – Reagents & Consumables and Instruments & Systems in USD Million

Chart 11: Glance at 2008, 2013 and 2018 Global In Vitro Diagnostics Market Share (%) by Product Type – Reagents & Consumables and Instruments & Systems

Chart 12: Global In Vitro Diagnostics Market Analysis (2008-2018) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology in USD Million

Chart 13: Glance at 2008, 2013 and 2018 Global In Vitro Diagnostics Market Share (%) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology

Chart 14: Global IVD Reagents & Consumables Market Analysis (2008-2018) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 15: Glance at 2008, 2013 and 2018 Global IVD Reagents & Consumables Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 16: Global IVD Instruments & Systems Market Analysis (2008-2018) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 17: Glance at 2008, 2013 and 2018 Global IVD Instruments & Systems Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 18: Global IVD Market Analysis in Clinical Chemistry Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 19: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Clinical Chemistry by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 20: Global IVD Market Analysis in Immunoassay Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 21: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Immunoassay by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 22: Global IVD Market Analysis in Diabetes Testing Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 23: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Diabetes Testing by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 24: Global IVD Market Analysis in Blood Testing Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 25: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Blood Testing by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 26: Global IVD Market Analysis in Molecular Diagnostics Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 27: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Molecular Diagnostics by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 28: Global IVD Market Analysis in Pathology Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 29: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Pathology by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 30: Global IVD Market Analysis in Cellular Analysis Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 31: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Cellular Analysis by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 32: Global IVD Market Analysis in Microbiology Applications (2008-2018) Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD Million

Chart 33: Glance at 2008, 2013 and 2018 Global Market Share (%) of IVD in Microbiology by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

PART B: REGIONAL MARKET PERSPECTIVEChart 34: The Projection of Largest Regions in terms of Market Growth for In Vitro Diagnostics by Geography – Asia-Pacific, South America, North America and EuropeChart 35: Global In Vitro Diagnostics Market Analysis (2008-2018) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in USD MillionChart 36: Glance at 2008, 2013 and 2018 Global In Vitro Diagnostics Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

REGIONAL MARKET OVERVIEW

NORTH AMERICAChart 37: North American In Vitro Diagnostics Market Analysis (2008-2018) by Geographic Region – United States, Canada and Mexico in USD MillionChart 38: Glance at 2008, 2013 and 2018 North American In Vitro Diagnostics Market Share (%) by Geographic Region – United States, Canada and MexicoChart 39: North American In Vitro Diagnostics Market Analysis (2008-2018) by Product Type – Reagents & Consumables and Instruments & Systems in USD MillionChart 40: Glance at 2008, 2013 and 2018 North American In Vitro Diagnostics Market Share (%) by Product Type – Reagents & Consumables and Instruments & SystemsChart 41: North American In Vitro Diagnostics Market Analysis (2008-2018) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology in USD MillionChart 42: Glance at 2008, 2013 and 2018 North American In Vitro Diagnostics Market Share (%) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and MicrobiologyChart 43: North American IVD Reagents & Consumables Market Analysis (2008-2018) by Geographic Region – United States, Canada and Mexico in USD MillionChart 44: Glance at 2008, 2013 and 2018 North American IVD Reagents & Consumables Market Share (%) by Geographic Region – United States, Canada and MexicoChart 45: North American IVD Instruments & Systems Market Analysis (2008-2018) by Geographic Region – United States, Canada and Mexico in USD MillionChart 46: Glance at 2008, 2013 and 2018 North American IVD Instruments & Systems Market Share (%) by Geographic Region – United States, Canada and MexicoChart 47: North American IVD Market Analysis in Clinical Chemistry Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 48: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Clinical Chemistry by Geographic Region – United States, Canada and MexicoChart 49: North American IVD Market Analysis in Immunoassay Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 50: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Immunoassay by Geographic Region – United States, Canada and MexicoChart 51: North American IVD Market Analysis in Diabetes Testing Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 52: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Diabetes Testing by Geographic Region – United States, Canada and MexicoChart 53: North American IVD Market Analysis in Blood Testing Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 54: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Blood Testing by Geographic Region – United States, Canada and MexicoChart 55: North American IVD Market Analysis in Molecular Diagnostics Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 56: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Molecular Diagnostics by Geographic Region – United States, Canada and MexicoChart 57: North American IVD Market Analysis in Pathology Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 58: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Pathology by Geographic Region – United States, Canada and MexicoChart 59: North American IVD Market Analysis in Cellular Analysis Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 60: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Cellular Analysis by Geographic Region – United States, Canada and MexicoChart 61: North American IVD Market Analysis in Microbiology Applications (2008-2018) Geographic Region – United States, Canada and Mexico in USD MillionChart 62: Glance at 2008, 2013 and 2018 North American Market Share (%) of IVD in Microbiology by Geographic Region – United States, Canada and Mexico

United States

Chart 63: United States In Vitro Diagnostics Market Analysis (2008-2018) by Product Type – Reagents & Consumables and Instruments & Systems in USD Million

Chart 64: Glance at 2008, 2013 and 2018 United States In Vitro Diagnostics Market Share (%) by Product Type – Reagents & Consumables and Instruments & Systems

Chart 65: United States In Vitro Diagnostics Market Analysis (2008-2018) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology in USD Million

Chart 66: Glance at 2008, 2013 and 2018 United States In Vitro Diagnostics Market Share (%) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology

CanadaChart 67: Canadian In Vitro Diagnostics Market Analysis (2008-2018) by Product Type – Reagents & Consumables and Instruments & Systems in USD MillionChart 68: Glance at 2008, 2013 and 2018 Canadian In Vitro Diagnostics Market Share (%) by Product Type – Reagents & Consumables and Instruments & SystemsChart 69: Canadian In Vitro Diagnostics Market Analysis (2008-2018) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology in USD MillionChart 70: Glance at 2008, 2013 and 2018 Canadian In Vitro Diagnostics Market Share (%) by Application Area – Clinical Chemistry, Immunoassay, Diabetes Testing, Blood Testing, Molecular Diagnostics, Pathology, Cellular Analysis and Microbiology

Mexico

Chart 71: Mexican In Vitro Diagnostics Market Analysis (2008-2018) by Pr

To order this report:In Vitro Diagnostic Industry: In Vitro Diagnostics - A Global Market Overview

Market Research Report

Check our

Industry Analysis and Insights

CONTACT
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Doctor Proposes Information Tech to Reduce Prescription Errors

Tue, 15 May 2012 07:12:56 +0000

A study found that drug-related errors accounted for about a quarter of all preventable patient injuries. The study estimated that between 10 percent and 15 percent of prescriptions contain errors.

MIAMI, FL, May 15, 2012 /24-7PressRelease/ -- Many people think medical malpractice consists mainly of sensational cases, like accidentally leaving medical instruments inside a surgery patient. The reality is that medical malpractice often takes a more mundane but equally dangerous form: illegible handwriting on drug prescriptions. For example, pharmacists often misread doctor's handwritten prescriptions and give patients the wrong dosage -- or even the wrong medication -- for their medical problems.

A study of Canadian hospitals found that drug-related errors accounted for about a quarter of all preventable patient injuries. Pharmacists in the study estimated that between 10 percent and 15 percent of prescriptions contain errors.

These prescription drug errors may seem out of place in today's digital age. In addition to illegible handwriting, many prescriptions use confusing trade names for drugs and abbreviations for timing and dosage.

Researchers say that the health care systems of Canada and the U.S. have the least developed information technology for patient record-keeping, prescriptions and other medical tasks. According to Dr. Richard Alvarez, the most significant barrier for electronic record-keeping is not financial costs, but rather the traditional work habits of medical professionals.

Some medical professionals are embracing Dr. Alvarez's efforts to reduce prescription drug errors. By computerizing the process, mistakes caused by poor handwriting, abbreviations and dosage errors could decrease substantially. Computer software could require doctors to double-check orders. A pharmacy would receive a computer printout of prescription information rather than an illegible note. Errors could still happen in manual entry of data, but in far fewer numbers.

Dr. Alvarez argues for the use of information technology across the health care system to allow any medical professionals, including emergency room doctors, to instantly view a patient's medical history for treatment purposes. This technology would allow pharmacists to check whether a doctor's prescription is inconsistent with a patient's other medical conditions, allergies or prescriptions, and alert the doctor of the problem. This is particularly important for older patients with longer medical histories and more frequent need for drug prescriptions. In addition, doctors would more easily be able to track whether patients were correctly filling prescriptions.

The attorneys at Ferrer Shane, PL, are Miami medical malpractice lawsuit lawyers who assist clients throughout south Florida with a variety of legal services. For more information about their Miami law firm, visit their Web site, http://www.ferrerlaw.com/ or call them at (305) 262-2728.

Location:

Ferrer Shane, PL

North Kendall Drive, Suite 260

Miami, FL 33176

Phone: 305-929-8684

Toll-free: (888) 609-5947

Additional Resources:

Personal Injury Legal Blog: http://www.ferrerlaw.com/blog/

Auto Accident Blog: http://www.miamimotorvehicleaccidentsattorney.com/

DUI & Traffic Ticket Blog: http://www.miami-dui-defense-attorney.com/

---

Press release service and press release distribution provided by http://www.24-7pressrelease.com

Novocure Announces Launch of Recurrent Glioblastoma Product Website

Mon, 14 May 2012 16:03:08 +0000

Novocure Announces Launch of Recurrent Glioblastoma Product Website

The website is a one-stop resource for patients and health care professionals seeking information on NovoTTF™ therapy for patients suffering from recurrent glioblastoma.

PR Newswire

PORTSMOUTH, N.H., May 14, 2012 /PRNewswire/ -- In its ongoing effort to help patients, their caregivers and health care professionals easily find detailed information about its NovoTTF™ therapy for recurrent glioblastoma, Novocure™ today unveiled its U.S.-focused NovoTTF™ Therapy Website, found at www.novottftherapy.com.

Novocure™, a commercial stage private oncology company, manufactures the NovoTTF™-100A,a wearable device that delivers tumor treating fields (TTFields) therapy to patients suffering from recurrent glioblastoma (GBM). TTFields therapy is specifically tuned to disrupt the uncontrolled division of cancer cells, resulting in cancer cell death while sparing healthy cells. The NovoTTF-100A™ system was approved by the U.S. Food & Drug Administration in 2011 for the treatment of recurrent GBM, the most common and deadliest form of primary brain tumor, after clinical studies demonstrated that the therapy was comparable to chemotherapy in extending overall survival, with minimal side effects and a better quality of life.

TTFields therapy is the first entirely novel cancer treatment modality to be introduced for recurrent glioblastoma patients since the introduction of chemotherapy. The website ensures that patients, their caregivers and health care professionals have access to the latest information on this groundbreaking therapy. The NovoTTF™ Therapy Website explains the science behind TTFields, and how the NovoTTF™-100A device is operated and worn to treat patients with recurrent glioblastoma. The website contains dedicated sections for patients and health care providers, an up-to-date list of treatment centers, a trouble shooting section and other patient resources. There is also contact information for Novocure's patient access and assistance program, technical support and staff members who can answer questions that visitors to the site may have.

About Glioblastoma

Glioblastoma (GBM) is the most aggressive and most common form of primary brain tumor. The disease affects approximately 10,000 Americans each year. The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the deadliest forms of cancer.

About the NovoTTF™-100A

The NovoTTF™-100A is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in both in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF™-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent GBM brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy. The NovoTTF™-100A has received marketing approval in the US and is a CE Marked device that is cleared for sale in Europe.

Approved Indication

The US Food and Drug Administration (FDA) approved the NovoTTF-100A System in April 2011 for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically– or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF™-100A under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.novottftherapy.com or by calling toll free 1-855-281-9301.

About Novocure™

SOURCE Novocure

Rise In Traumatic Brain Injuries Among Teens

Sat, 12 May 2012 07:13:48 +0000

In South Carolina and around the country, teenagers are suffering traumatic brain injuries at higher rates than ever before.

May 12, 2012 /24-7PressRelease/ -- The media have drawn attention to the problem of brain injuries in teens by focusing on the increased likelihood of receiving such injuries from participation in contact sports like football and hockey. After all, males between the ages of 14 and 24 are at the highest risk of sustaining a brain injury. Team sports are not the cause of the majority of those injuries, though; teenagers are far more likely to suffer a traumatic brain injury during a motor vehicle collision than a football game.

According to information provided by The Children's Hospital of Philadelphia, about 30 percent of teens injured in auto accidents suffer from concussions, skull fractures, subdural hematomas and traumatic brain injuries. The data were based on a new study commissioned by the hospital that reviewed serious injuries sustained by more than 55,000 teenage drivers and passengers involved in car accidents in 2009 and 2010.

Lasting Effects of Brain Injuries

Researchers are voicing concerns over the "burden of motor vehicle crash-related brain injuries on families and the Nation's health care system." The study further reports that "full recovery from serious head injuries is often not achievable."

Dennis R. Durbin, MD, MSCE, lead author of the report and co-scientific director for the Center for Injury Research and Prevention at The Children's Hospital of Philadelphia, states that there are often significant life-long effects of these types of injuries on both the teenage victims themselves and their families.

Serious Injuries Can Impair Brain Development

A brain injury is defined as a physiological disruption of brain function that results from trauma to the head. It is usually the result of a rapid movement of the head followed by an abrupt stop, which causes the brain to shift within the encasement of the skull.

The initial distinction between a mild and moderate brain injury can be difficult, particularly if there are no outward signs of trauma. Even so, a relatively "mild" brain injury like a concussion could possibly lead to permanent disability or mental deficits. Teenagers and children are more susceptible to long-lasting effects of brain injuries because their brains are still developing. Those who suffer from moderate to severe brain injuries are likely to endure physical, cognitive and behavioral impairment for months, years or the rest of their lives following the accident.

Traumatic brain injuries can cause such varied effects as:

- Speech, vision, hearing and other sensory impairments

- Chronic headaches

- Confusion

- Seizures

- Memory loss

- Attention and concentration issues

- Depression

- Anxiety

- Loss of cognitive function or analytical reasoning skills

Managing these impairments can be stressful and expensive. If you or a teenaged loved one is injured as the result of another driver's negligence, compensation may be available to cover medical and rehabilitative costs as well as pain and suffering. As a result, it is best to discuss your unique situation with an experienced car accident attorney in order to best preserve your legal rights and remedies.

Article provided by Mark C. Tanenbaum, P.A.

Visit us at www.tanenbaumlaw.com

---

Press release service and press release distribution provided by http://www.24-7pressrelease.com

MarijuanaInc.TV and Elkhyde Holdings LLC Sign MOU to Film Documentary of Cancer Warrior Cash Hyde, Montana's Youngest Medical Cannabis Card Holder

Thu, 10 May 2012 04:51:00 +0000

MarijuanaInc.TV and Elkhyde Holdings LLC Sign MOU to Film Documentary of Cancer Warrior Cash Hyde, Montana's Youngest Medical Cannabis Card Holder

PR Newswire

LAS VEGAS, May 10, 2012 /PRNewswire/ -- MARIJUANA, INC. (OTC: HEMP) or (HEMP.PK) is proud to announce the signing of a Memorandum of Understanding between its Media Division, MarijuanaInc.TV (www.mjinctv.com) and Elkhyde Holdings LLC to produce a film documenting the challenges faced and overcome by the Hyde family, whose young son Cash was diagnosed with brain cancer at age 2, and how the use of cannabis helped offset the side effects of chemotherapy (http://www.youtube.com/watch?v=tmviQBB5DHs).

Production of the documentary will begin this month at MarijuanaInc.TV/ Glass Slipper Studio in West Hollywood, California. Hal Lewis will produce the documentary, taking time from a demanding schedule following his participation as head of audio/video in the movie "The Artist" which won five Academy Awards including Best Film of 2012.

Release of the Cash Hyde documentary is projected for August of 2012. The film will be submitted for entry into the 2013 Sundance Film Festival.

The MOU states that the Hyde family will have final editorial approval, to ensure accuracy. The story line will follow the tumultuous events that occurred during Cash's battle with cancer, and to show the circumstances leading to the decision to administer cannabis to the toddler as well as the quest to gain safe access to the proper quality medical cannabis oil to treat Cashy.

"We're ready to begin production as soon as the Hyde family is available," said company President David Tobias. "A block of studio time is allocated to film Mike Hyde in studio at the end of May. Editing will be completed later this summer. In the interim, we intend to promote the film at coming events including the Connisseur Kulture show at the Barker Hanger in Santa Monica on May 11/12 and at the High Times Cannabis Cup in San Francisco in June."

CEO Bruce Perlowin added, "We have been supporters of the Cash Hyde Foundation since we co-sponsored the Art of Mary Jane Magazine's Fundraiser for Cashy in Hollywood last December (http://www.youtube.com/watch?v=zrnQ5huDc3Y0). By producing this documentary, we will raise awareness for the Cash Hyde Foundation and other young cancer warriors."

MarijuanaInc.TV will continue to provide coverage of pertinent events in the medical marijuana and hemp arenas in the coming months. Watch the coverage on www.marijuanainc.tv and www.hemp.com.

MARIJUANAINC.TV CREW FILMING AT THE CONNOISSEUR KULTURE SHOW MAY 11-12, BARKER HANGAR IN SANTA MONICA, CALIFORNIA

Your business' visibility can be expanded by video! Let the professionals of MarijuanaInc.TV's team featuring Segment Producer Stephanie Bishop and Henry Hemp film your concepts at the Conoisseur Kulture Show Booth 115. Meet CEO Bruce Perlowin, who will be autographing "The Golden Gate Smuggling Company." Make an appointment! See you there! Check out the CK Show teaser produced by MarijuanaInc.TV by clicking the link:

http://www.mjinctv.com/index.php/video/89/ck-expo-live-with-snoop-doog-may-11th-12th

ABOUT MARIJUANA, INC.

Marijuana, Inc. (HEMP.pk) focuses on the peripheral businesses created by the quickly emerging, and growing, multibillion dollar medical marijuana and hemp industries. Marijuana, Inc. (HEMP.pk) is not involved in the cultivation or marketing of medical marijuana. It is the company's belief that legalization of marijuana on a federal level will come to pass for all 50 states. With that in mind, the company is building infrastructure with the potential to gain substantial market share once marijuana prohibition ends.* (Pending any federal licensing or other requirements, that may be enacted after marijuana prohibition ends).

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Marijuana, Inc. to be materially different from the statements made herein.

CONTACT

info@marijuanainc.tv

http://marijuanainc.biz (Corporate Website)

http://www.hemp.com (Everything Hemp Division)

http://www.marijuanainc.tv (Media and Entertainment Division)

http://www.KushClear.com (Hemp Based Supplements Division)

http://www.Twitter.com/Marijuanainc (Twitter)

http://www.Facebook.com/BrucePerlowin (CEO Fan Page)

http://www.twitter.com/BrucePerlowin (CEO Tweets)

http://www.youtube.com/watch?v=88d8aYNC2LM (Supporting Bobby Platshorn and The Silver Tour)

http://www.youtube.com/watch?v=zrnQ5huDc3Y&feature=youtu.be (Supporting Cash Hyde Foundation)

Phone: 1-877-221-8351

SOURCE Marijuana, Inc.